Dexcom has unveiled its next-generation continuous glucose monitoring system, Dexcom G8, during the company’s Investor Day presentation, positioning the product as a major advancement in real-time glucose monitoring technology.
CEO Jake Leach described G8 as a “completely new product platform” built on a redesigned silicon chip, updated algorithms, and advanced sensing capabilities that have been in development at the company for decades.
“The G8 system has additional technology built in, based on a whole new silicon chip, design and algorithm,” Leach said during the event. “Actually, this has been a development for several decades at Dexcom because we've always had this idea of trying to do this, but now we're finally proving the feasibility that we can make this happen in the G8 product.”
According to the company, the G8 platform incorporates technology capable of measuring additional physiological signals beyond glucose levels. Dexcom said these enhancements allow the system to adapt to physiologic changes in real time, improve consistency, and reduce outlier readings. The company also stated that the device is designed to self-adapt to individual users over time.
The new sensor features a form factor that is 50% smaller than Dexcom’s current G7 device while maintaining advanced sensing functionality.
Dexcom indicated that regulatory submission plans are underway, with an FDA submission expected next year. Commercial launch timing is projected for late 2027 or early 2028, depending on regulatory review timelines.
“Our teams are marching rapidly towards [FDA] submission of this product next year that will facilitate a launch either at the end of 2027 or early 2028, depending on the regulatory review timing,” Leach said.
The company also highlighted continued momentum for its existing G7 portfolio, including the G7 10 Day and G7 15 Day products, and said it intends to build on that adoption with the G8 rollout.
In addition to the hardware announcement, Dexcom introduced updates to its Stelo application, including trend tracking, pattern analysis, an AI-powered coaching feature, and a virtual assistant intended to provide personalized glucose insights.
Dexcom further stated that it expects a Medicare coverage decision before the end of 2026, with coverage anticipated to begin next year and potentially extend access to approximately 12 million individuals.
The company also outlined broader growth plans, including executive expansion in the U.S. and additional product launches in India, Brazil, and Mexico.
Click here for the original news story.
